Prostate-targeted mTOR-shRNA inhibit prostate cancer cell growth in human tumor xenografts

International Journal of Clinical and Experimental Medicine

Volumn 6, Issue 2, 2013, Pages 126-132

  Du, Yue Feng ^a   Long, Qing Zhi ^a   Shi, Ying ^b   Liu, Xiao Gang ^a   Li, Xu Dong ^a   Zeng, Jin ^a   Gong, Yong Guang ^a   Wang, Xin Yang ^a   He, Da Lin ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Apoptosis; MTOR; Prostatic carcinoma; PSMA

Indexed keywords

LENTIVIRUS VECTOR; MAMMALIAN TARGET OF RAPAMYCIN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SHORT HAIRPIN RNA;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOLECULAR CLONING; MOUSE; NICK END LABELING; NONHUMAN; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR VOLUME; VIRUS PARTICLE; VIRUS TITRATION; WESTERN BLOTTING;

EID: 84873110534     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Carter HB, Ferrucci L, Kettermann A, Landis P, Wright EJ, Epstein JI, Trock BJ and Metter EJ. Detection of life-threatening prostate cancer with prostate-specifc antigen velocity during a window of curability. J Natl Cancer Inst 2006; 98: 1521-1527.
3. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2: 584-593.
4. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA and Sellers WR. mTOR inhibition reverses Akt-de-pendent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-de-pendent pathways. Nat Med 2004; 10: 594-601.
5. Heston WD. Characterization and glutamyl preferring carboxypeptidase function of prostate specifc membrane antigen: a novel folate hydrolase. Urology 1997; 49: 104-112.
6. Lundwall A, Malm J, Clauss A, Valtonen-Andre C and Olsson AY. Molecular cloning of complementary DNA encoding mouse seminal vesicle-secreted protein SVS I and demonstration of homology with copper amine oxidases. Biol Reprod 2003; 69: 1923-1930.
7. Pinto JT, Suffoletto BP, Berzin TM, Qiao CH, Lin S, Tong WP, May F, Mukherjee B and Heston WD. Prostate-specifc membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 1996; 2: 1445-1451.
8. Murphy GP, Elgamal AA, Su SL, Bostwick DG and Holmes EH. Current evaluation of the tissue localization and diagnostic utility of prostate specifc membrane antigen. Cancer 1998; 83: 2259-2269.
9. Conway RE, Petrovic N, Li Z, Heston W, Wu D and Shapiro LH. Prostate-specifc membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol 2006; 26: 5310-5324.
10. Cernilogar FM, Onorati MC, Kothe GO, Burroughs AM, Parsi KM, Breiling A, Lo Sardo F, Saxena A, Miyoshi K, Siomi H, Siomi MC, Car-ninci P, Gilmour DS, Corona DF and Orlando V. Chromatin-associated RNA interference components contribute to transcriptional regulation in Drosophila. Nature 2011; 480: 391-395.
11. Chen T, Heller E, Beronja S, Oshimori N, Stokes N and Fuchs E. An RNA interference screen uncovers a new molecule in stem cell self-renewal and long-term regeneration. Nature 2012; 485: 104-108.
12. Jiang L, Lai YK, Zhang J, Wang H, Lin MC, He ML and Kung HF. Targeting S100P inhibits colon cancer growth and metastasis by Lentivi-rus-mediated RNA interference and proteomic analysis. Mol Med 2011; 17: 709-716.
13. Petrocca F and Lieberman J. Promise and challenge of RNA interference-based therapy for cancer. J Clin Oncol 2011; 29: 747-754.
14. Li M and Rossi JJ. Lentiviral vector delivery of siRNA and shRNA encoding genes into cultured and primary hematopoietic cells. Methods Mol Biol 2008; 433: 287-299.
15. Kim DH, Behlke MA, Rose SD, Chang MS, Choi S and Rossi JJ. Synthetic dsRNA Dicer substrates enhance RNAi potency and effcacy. Nat Biotechnol 2005; 23: 222-226.
16. Dumont FJ and Su Q. Mechanism of action of the immunosuppressant rapamycin. Life Sci 1996; 58: 373-395.
17. Law BK. Rapamycin: an anti-cancer immuno-suppressant? Crit Rev Oncol Hematol 2005; 56: 47-60.
18. Windecker S, Roff M and Meier B. Sirolimus eluting stent: a new era in interventional cardiology? Curr Pharm Des 2003; 9: 1077-1094.
19. Gao XM, Wong G, Wang B, Kiriazis H, Moore XL, Su YD, Dart A and Du XJ. Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fbrosis. J Hypertens 2006; 24: 1663-1670.
20. Simler NR, Howell DC, Marshall RP, Goldsack NR, Hasleton PS, Laurent GJ, Chambers RC and Egan JJ. The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fbrosis in rats. Eur Respir J 2002; 19: 1124-1127